Q2 2025 Compass Therapeutics Inc. Earnings Call Transcript
Key Points
- Compass Therapeutics Inc (CMPX) reported fewer total deaths than projected in their ongoing trial for tovecimig, indicating potential positive effects on patient survival.
- The company observed two deep partial responses in early dose escalation cohorts for CTX-8371, their PD-1/PD-L1 bispecific antibody, in patients with non-small cell lung cancer and triple-negative breast cancer.
- Preclinical studies showed that CTX-10726, their PD-1 VEGF bispecific antibody, demonstrated superior tumor control compared to ivonescimab and was equivalent to pembrolizumab.
- Compass Therapeutics Inc (CMPX) has a strong cash position with $101 million, providing a runway into 2027 to support ongoing and future clinical programs.
- The company plans to initiate several cohort expansions and new studies, including a basket study for tovecimig and expansions for CTX-8371, indicating a robust pipeline and future growth potential.
- The analysis of progression-free survival (PFS) and overall survival (OS) for tovecimig has been delayed to Q1 2026 due to fewer deaths than expected, potentially impacting timelines for regulatory submissions.
- There is uncertainty regarding the potential breakthrough designation for tovecimig, as discussions with the FDA are ongoing and contingent on future data readouts.
- The company has not yet provided data on the duration of response for tovecimig, leaving questions about the long-term efficacy of the treatment.
- The competitive landscape for PD-1/PD-L1 inhibitors, particularly in non-small cell lung cancer, poses challenges for market differentiation and regulatory approval pathways.
- The company has not yet finalized the doses for the expansion cohorts of CTX-8371, indicating ongoing uncertainty in the optimal dosing strategy.
Greetings, and welcome to Compass Therapeutics second quarter 2025 Earnings and Business Update Call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to introduce Anna Gifford, Chief of Staff. Thank you. You may begin.
Good morning, and thank you for joining us. My name is Anna Gifford. I'm Chief of Staff at Compass Therapeutics. With me today is Dr. Thomas Schuetz, CEO and Vice Chair of the Compass Board. Our CFO, Barry Shin, will also join us for a short Q&A following Tom's comments. Earlier this morning, we released our financial results and a business update for the second quarter. The slide presentation accompanying this webcast and a copy of the press release are available on our website. Please note, we'll be making forward-looking statements on today's webcast. These forward-looking statements are described in our press release issued today and the company's SEC filings. With that, I'd like to turn the call over to Thomas Schuetz. Tom?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
